Compare FFIN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIN | CRSP |
|---|---|---|
| Founded | 1890 | 2013 |
| Country | United States | Switzerland |
| Employees | 1500 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.1B |
| IPO Year | N/A | 2016 |
| Metric | FFIN | CRSP |
|---|---|---|
| Price | $32.05 | $56.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $37.50 | ★ $71.50 |
| AVG Volume (30 Days) | 905.9K | ★ 1.6M |
| Earning Date | 01-22-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 16.54 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $581,881,000.00 | $38,337,000.00 |
| Revenue This Year | $21.45 | N/A |
| Revenue Next Year | $6.75 | $718.51 |
| P/E Ratio | $18.35 | ★ N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $29.44 | $30.04 |
| 52 Week High | $39.12 | $78.48 |
| Indicator | FFIN | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 53.32 |
| Support Level | $29.44 | $52.10 |
| Resistance Level | $31.00 | $60.73 |
| Average True Range (ATR) | 0.72 | 2.33 |
| MACD | 0.11 | 0.31 |
| Stochastic Oscillator | 89.29 | 55.74 |
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.